ADC Development Services Targeting AXL

Antibody-drug conjugate (ADC) represents a novel type of immunotherapy in the cancer treatment. Approved ADCs and other investigated ADCs have shown great promise and potential in patients with cancer disease. As one of the pioneer companies in the field of bioconjugation services, Creative Biolabs focuses on novel ADCs discovery and development for many years. We provide a wide range of ADCs development services against solid tumors with our state-of-art technology platforms. Our services include synthetic route design and optimization, complex conjugates production and characterization. We are confident to offer high-quality and cost effective ADCs service for our clients.

Introduction of AXL

AXL, also known as AXL receptor tyrosine kinase, is an enzyme encoded by the AXL gene that located at 19q13.1-q13.2. It belongs to the receptor tyrosine kinase subfamily. AXL contains an extracellular structure, two immunoglobulin-like repeats and an intracellular tyrosine kinase domain. AXL plays a role in the stimulation of cell proliferation and survival. It is also involved in mediating cell aggregation by homophilic binding. Besides, AXL acts as an inhibitor in the innate immune response to dampen NK cell activity. This protein exists in bone marrow stroma, myeloid cells, tumour cells and tumour vasculature. Moreover, AXL is highly expressed on many solid tumor types such as triple-negative breast cancer (TNBC), acute myeloid leukemia (AML), non-small-cell lung cancer (NSCLC), pancreatic cancer and ovarian cancer and it is involved in tumor cell proliferation, migration, and invasion. Thus, AXL has been regarded as a promising target in the cancer treatment.

The diagram depicts the structure of the AXL gene (bottom) roughly aligned with its corresponding functional protein domains (top). Fig.1 The diagram depicts the structure of the AXL gene (bottom) roughly aligned with its corresponding functional protein domains (top).

Anti-AXL ADC in Solid Tumors

AXL as a target has been used in the ADC development for the treatment of solid tumors. For example, Enapotamab vedotin (HuMax®-AXL-ADC), an ADC targeted AXL, is composed of an anti-AXL antibody linked to the cytotoxic drug monomethyl auristatin E (MMAE) through a protease-cleavable linker. Preclinical studies demonstrated that Enapotamab vedotin has high affinity binding to AXL and potent antitumor activity to induce cytotoxicity in vitro and in vivo in solid tumors xenograft model. In addition, the ADC presents good response rate and tolerable safety profile and currently is investigated in the clinical phase I trial.

Enapotamab vedotin represents a promising strategy to increase tumor response and combat drug resistance. Fig.2 Enapotamab vedotin represents a promising strategy to increase tumor response and combat drug resistance. (Boshuizen, 2018)

What Can We Do for You?

Creative Biolabs is an acknowledged service provider in ADCs development. We are committed to offering complete ADCs design, production and characterization services. Besides, we also provide a variety of ADCs related products such as specific antibodies, potent drugs or linker-payloads. Our services and products will promote your innovative ADCs drug development. Please contact us for more information if you are interested in our services.

Our ADCs development services including:

References

  1. Boshuizen, J.; et al. Cooperative targeting of melanoma heterogeneity with an AXL antibody-drug conjugate and BRAF/MEK inhibitors. Nature medicine. 2018, 24(2): 203.

For lab research use only, not for any in vivo human use.


Related Sections

Disease Research:
Online Inquiry
Name:
*Phone:
*E-mail Address:
*Products or Services Interested:
Company/Institution
Project Description:
*Verification Code:
Verification code
Click image to refresh the verification code.


Welcome! For price inquiries, please feel free to contact us through the form on the left side. We will get back to you as soon as possible.


Contact us
USA
 45-1 Ramsey Road, Shirley, NY 11967, USA
 Tel: 1-631-357-2254
 Fax: 1-631-207-8356
 Email:
Europe
UK - Germany
Email:


Inquiry

Top